Skip to content
HealthTech Seed Founded 2023

Ability

Developer of modulating biotherapeutics to address cancer and autoimmune diseases

📍 Montreal, Canada · Life Sciences Tech

Funding snapshot

Last roundSeed
Amount$18M
Date18 June 2024

About

Developer of modulating biotherapeutics to address cancer and autoimmune diseases. It has AbiLeap discovery engine that combines continuously learning AI with an extensive database of antigen-antibody interactions to generate fully human, IgG-based multispecific antibodies across cancer and autoimmune applications. The pipeline includes Leap 1121 for auti-immune disease, Leap 1009 and 1030 for solid tumors.

Latest news

No articles yet.

Raising like Ability?

Analyze your pitch deck before your next raise.

Analyze My Deck →